The ASCO conference is set to deliver promising readouts for several compounds targeting LAG3 including data from BMS that could lead to the first registrational filing for a next-generation checkpoint blocker.
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
Clinical: LAG3 to steal the spotlight from TIGIT at this year’s ASCO
Regeneron Pharmaceuticals also presented data on its anti-LAG3 antibody in melanoma. Another readout that was presented by Merck & Co strengthens the case for LAG3 inhibition as a strategy to expand the patient population responding to checkpoint inhibitors. Data from Immute add to the body of evidence that modulating different functions of the LAG3 pathway outside of T cells may also have antitumor effects.
In an abstract released ahead of ASCO, BMS reported that the combination of anti-LAG3 antibody relatlimab and its PD-1 blocker Opdivo doubled PFS to 10.1 months over 4.6 months for patients treated with Opdivo alone in the Phase 2/3 RELATIVITY-047 study in first-line melanoma. Last year’s ASCO spotlight was on TIGIT, which is differentiated from the rest of the checkpoint pack by its impact on both T and NK cells. The TIGIT pipeline has been rapidly expanding after last year’s Phase 2 readout of tiragolumab from Genentech, but there are no late-stage clinical advances since the meeting.
